On June 7, 2021 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology,reported that Thierry Guillaudeux, Ph.D., SVP Immuno-oncology at Kineta, will participate in the virtual symposium "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond," taking place on June 18, 2021 (Press release, Kineta, JUN 7, 2021, View Source;utm_medium=rss&utm_campaign=kineta-to-participate-in-vista-a-new-immune-checkpoint-in-cancer-autoimmunity-and-beyond-virtual-symposium [SID1234583660]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The symposium will focus on the emerging checkpoint molecule VISTA, its function, the role it plays in several disease areas and current development programs. The event will be hosted by Randolph Noelle, Ph.D., Professor of Microbiology and Immunology, Department of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth; and Padmanee Sharma, M.D., Ph.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center.
Presentation Details:
Dr. Guillaudeux will participate on the following panels during the Symposium:
Session Title: Discovery of Anti-VISTA Antibodies
Date/Time: June 18, 2021 from 9:50 AM to 10:35 AM Eastern Time
Session Title: VISTA Advances into Clinical Development
Date/Time: June 18, 2021 from 12:20 PM to 1:05 AM Eastern Time
To access the panel discussion please register as an attendee here: https://bit.ly/3hBzIUj
"I am pleased to participate in this exciting event", said Thierry Guillaudeux of Kineta. "VISTA is an important target that I believe has a central role in converting cold, hard-to-treat tumors into hot tumors that are more susceptible to treatment. This myeloid checkpoint has the potential to improve cancer management for patients in a variety of solid tumors,"
Kineta is developing KVA12.1, a novel anti-VISTA antibody in preclinical evaluation for the treatment of solid tumors. VISTA is a key driver of the immunosuppressive tumor microenvironment (TME) and is overexpressed on myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs). It is a critical myeloid cell immune-checkpoint, and VISTA blockade can reprogram suppressive myeloid cells and reactivate antitumor immune function. Blocking VISTA activates an immune cell cascade that increases T cell effector functions to drive an efficient anti-tumor response. Preclinical studies have demonstrated single agent anti-VISTA activity but also demonstrate that targeting VISTA in combination with PD-1, PD-L1 or CTLA-4 can significantly improve the efficacy of those checkpoint inhibitors.